We are pleased to welcome Dr. Herve Tiriac from UC SanDiego as the new vice chair of the ARTNet Inflammatory Microenvironment & Tumor Cross Talk Working Group.

Congratulations to Dr. Mark Long from the ARTNet CDMC U24 @roswellpark.bsky.social on being elected co-chair of the Functional Screens & Assay Development WG! The WG is working on leveraging high-throughput methods to understand and combat acquired resistance to therapeutics.

Panel Discussion # 2 focused on ARTNet's collaborative approach to translating resistance biology into therapheutic strategies. #ARTNetScientificRetreat2025

Cell States, Metabolism and Inflammatory Microenvironment WG shared updates on spatial multi-omics projects tackling therapy resistance in lung, pancreatic & breast cancers, and a joint white paper with PSRC. #ARTNetScientificRetreat2025

Dr. Seth Gammon presented updates from the Functional Screens&Assay Development WG. Highlights included a new white paper on targeting acquired resistance, a pilot grant on novel screening & collaborative efforts to uncover shared drug vulnerabilities. #ARTNetScientificRetreat2025

Dr. Alan Hutson shared updates from the ARTNet CDMC U24 @roswellpark.bsky.social, featuring new resource-sharing catalogs, collaborative research initiatives, and AI-driven tools to enhance cancer research and foster cross-network collaboration. #ARTNetScientificRetreat2025

#ARTNetScientificRetreat2025 Poster Session

Flash Talks for Poster Presenters featured research with translational potential: Katherine Dempsey from PCAC U54 explored SAT1 & CAF polarization in pancreatic cancer. #ARTNetScientificRetreat2025

#ESITalk: Dr.Vincent Bernard (ARTI U54) @mdanderson.bsky.social revealed how spatial profiling uncovers persister cell populations and immune reshaping after radiation in pancreatic cancer. Targeting KRAS and ferroptosis/cuproptosis defenses may improve radiosensitivity #ARTNetScientificRetreat2025

#ECITalks: Melissa Stewart from AML U54 @ohsuknight.bsky.social shared how combining venetoclax with the CDK4/6 inhibitor palbociclib overcomes resistance in RAS-mutant AML, reducing tumor burden, improving survival, and reshaping protein synthesis pathways. #ARTNetScientificRetreat2025

#ECITalk: Dr. Moran Amit from H-CARR U54 at @mdanderson.bsky.social shared how tumor-associated nerves drive cancer progression, #metastasis, and therapy resistance. Targeting the neural-tumor microenvironment opens new paths for cancer treatment and #immunotherapy. #ARTNetScientificRetreat2025

#ECITalk: Dr. Surendra Shukla from ARTNet PCAC U54 shared how BACH1 drives pancreatic cancer progression and FOLFIRINOX resistance. Targeting BACH1, directly or with hemin, enhances therapy efficacy and reveals PDIA6 as a key player in unfolded protein response. #ARTNetScientificRetreat2025

Dr. Trever Bivona from BAATAAR-UP center shared findings of how tumor lineages adapt to targeted therapy in EGFR-mutant #lungcancer. Combination strategies such as osimertinib+sonidegib can overcome resistance driven by transcriptional plasticity tinyurl.com/43d6sma4 #ARTNetScientificRetreat2025

Dr. Jeffrey Tyner (ARTNet AML center) highlighted how AML cell differentiation states govern therapy response & resistance. His team developed Myelo-ID, a rapid gene expression test that predicts outcomes & helps guide treatment decisions. Read more: tinyurl.com/kpt3483z #ARTNetScientificRetreat2025

Dr. Jeffrey Myers shared advances in overcoming cisplatin resistance in head & neck cancer, highlighting NRF2-driven resistance, immune suppression, and novel biomarkers like HP-MRI and exosomal miRNAs for precision therapy. More info: nciartnet.org/en/members/h... #ARTNetScientificRetreat2025

Dr. Pankaj Singh shared updates from the Pancreatic Cancer ARTNet Center (PCAC), highlighting metabolic drivers of resistance, MUC1-mediated exosome signaling, and targeting Cyclin K to overcome therapy resistance More on ARTNet PCAC center: nciartnet.org/en/members/p... #ARTNetScientificRetreat2025

Drs. Boyi Gan & Dadi Jiang from MD Anderson shared advances from the ARTI Center, exploring ferroptosis&other cell death pathways to overcome tumor radioresistance, highlighting CRIP1-PP2A-MTF1 signaling & therapeutic strategies targeting cuproptosis. More on ARTI center: tinyurl.com/y85z5yua

Panelist Dr. Pankaj Singh highlighted cancer disparities among American Indian and Alaska Native populations, emphasizing systemic inequities, limited tissue access, and lack of models. #ARTNetScientificRetreat2025

Panelist Dr. Chinthalapally V. Rao of OUHealthScience highlighted stark disparities in colorectal cancer among African American & American Indian/Alaska Native populations in Oklahoma, linking molecular differences, inflammation, and access to care to survival outcomes. #ARTNetScientificRetreat2025

Panelist Dr. Victoria Seewaldt of City of Hope presented research on treatment-resistant triple-negative breast cancer, revealing early aggressive tumor microenvironment biology and highlighting complement C3 as a potential target for therapy. #ARTNetScientificRetreat2025

Panelist Dr. Jose Trevino of VCUHealth highlighted efforts to address cancer health disparities through the U4HELPP program and Rapid Autopsy Program, advancing understanding of pancreatic cancer and metastatic disease. #ARTNetScientificRetreat2025 #CancerResearch

Panel Discussion: Clinical Patterns and Biological Mechanisms of Outcome Disparities and Acquired Resistance. Moderator: Dr. Jeffrey Tyner Panelists: Dr. Jose Trevino, Dr. Victoria Seewaldt, Dr. Chinthalapally V. Rao, and Dr. Pankaj Singh #ARTNetScientificRetreat2025

At #ARTNetScientificRetreat2025, keynote speaker Dr. Veronica Galvan Hart, shared insights on how aging and cellular senescence connect Alzheimer’s disease and cancer, highlighting tau-induced senescence and opportunities for early intervention. Learn more about her research: galvanlab.org

Dr. Robert Mannel, Director of Stephenson Cancer Center, introduced the OU Health Stephenson Cancer Center (SCC) #ARTNetScientificRetreat2025

Dr. Ian Dunn, Executive Dean of the College of Medicine Chief Academic Officer, introduced the University of Oklahoma Health Sceince Center. #ARTNetScientificRetreat2025

Two days of the #ARTNetScientificRetreat2025 are taking place at the University of Oklahoma Health Science Center. hosted by our OUHSC U54 Center PI, Dr. Pankaj Singh.

Check out the paper out now @nature.com describing the mechanism of resistance to anti-PD-1 therapy elucidated by ARTNet investigator Dr. Moran Amit @mdanderson.bsky.social

FYI: @sitcancer.bsky.social and NCI sponsored free webinar focused on assessing TME with systems Immunology,as part of the Computational Immuno-Oncology Series is taking place tomorrow, August 21st at 12 PM ET. Register at: sitcancer.org/CompIO

The global burden of liver cancer is increasing. 📈 Hepatocellular carcinoma (HCC) accounts for approximately 80% of cases globally. 💡 A new Commission outlines evidence-based recommendations for action to reduce the global HCC burden: tinyurl.com/yzxvktkw

Online now: Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers

A bacterially produced molecule circulates in the bloodstream and increases the risk of cardiovascular disease by hijacking immune-cell signalling go.nature.com/4f5tAPN

New from the CAP-IT MGUS U54 Center @bcmhouston.bsky.social in Cancer Biomarkers: The Polyclonal Plasma Cell (PolyPC) signature is a strong negative predictor of MGUS progression to multiple myeloma. 📖 doi.org/10.1177/1875... #Myeloma #MGUS #CancerBiomarkers #Hematology #CAPITPublication

Don't wait - register now for the CAP-IT Virtual Annual Summit on July 24, 2025! Open to the public with exciting talks on cancer prevention and interception. 🔗 Register: tinyurl.run/M3wsBV ℹ️ Info: ncicapit.org 📧 [email protected] #CancerPrevention #NCICAPIT

Reactome is an open-source, peer-reviewed pathway database providing intuitive tools for visualizing and analyzing molecular pathways. Co-led by Dr. Guanming Wu of ARTNet U54 at @ohsunews.bsky.social. Explore: reactome.org More tools: ARTNet Software Sharing Catalog nciartnet.org/en/resources...

This new paper from ARTNet U24 center @roswellpark.bsky.social proposes a machine learning-assisted inferential procedure under Rosenbaum’s exact test framework—replacing linear models with flexible nonparametric ones. #ARTNetPublication www.nature.com/articles/s41...

Just published in Immunity: Mutant p53 hijacks enhancers to boost immunosuppressive chemokines, undermining immune checkpoint blockade in pancreatic cancer. 🔗 t.co/uy8xVALqyn #CancerImmunology #PancreaticCancer #p53 #ImmunityJournal

If you use Spearman (or Pearson) correlation p-values from standard software… there's a 99.9% chance they’re wrong. Drs. Han Yu and Alan Hutson of @roswellpark.bsky.social reveal why and offer a robust fix in this top-cited article: www.tandfonline.com/doi/full/10.... #ARTNetPublication #biostats

New study reveals that tumor necrosis factor (TNF) can reprogram macrophage #efferocytosis from silent to pro-inflammatory during #sepsis and systemic inflammation. Read in Science Immunology: scim.ag/45Yvj6Y

Online Now: CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma

New study from the ARTNet BAATAAR-UP center in @jtoonline.bsky.social: Targeting WEE1 may overcome osimertinib resistance driven by ARID1A mutations in EGFR-mutant lung cancer. #NSCLC #ARTNetPublication pubmed.ncbi.nlm.nih.gov/40518016/#fu...

New in #JITC: In chemo-resistant colorectal cancer, targeting TBK1 boosts oncolytic virotherapy by enhancing ICAM1-driven NK cell immunity. 🧬 Read more: bit.ly/4kSNTlB

We’re excited to announce that the CAP-IT Virtual Annual Summit will be held on July 24, 2025! Register here: docs.google.com/forms/d/e/1F... For more information, visit : ncicapit.org or email: [email protected] #CancerPrevention #NCICAPIT

🚨Roadmap 🚨 Alice Soragni @alice.soragnilab.com‬, Erik S. Knudsen ‪@roswellpark.bsky.social‬ ‪ & Co discuss the mechanisms of acquired resistance and the models to better study it to advance predictive and proactive prevention in cancer therapy. 📖 ⬇️

🎉 The #ARTNet roadmap article is now published in Nature Review Cancer. Kudos to former Functional Screens & Assays WG chairs Drs. Alice Soragni @alice.soragnilab.com & Erik Knudsen, and all WG members for their valuable contributions! #ARTNetPublication www.nature.com/articles/s41...

Acute myeloid leukemia is one of the most difficult to treat cancers in children and adolescents/young adults due to high rates of chemoresistance and relapse. buff.ly/ho1iRCm #hemesky

New study decodes resistance to immune checkpoint inhibitors in NSCLC using plasma proteomics. Insights into personalized therapy & drug targets from 388 resistance-associated proteins (RAPs). #NSCLC #Immunotherapy #Proteomics jitc.bmj.com/content/13/5...

How can machine learning unlock insights from multimodal data in immunotherapy? Join the Lessons from the CIMAC-CIDC Network webinar to explore patient heterogeneity and treatment response modeling. 🎓 FREE registration: sitcancer.org/CompIO #SITC #NCI #Immunotherapy #CompIO

New research reveals that therapy resistance in acute myeloid leukemia is linked to specific disease subsets—where cell differentiation status shapes response to BCL-2 inhibition. 🔗 ow.ly/OVYy50VXkPq #myeloidneoplasia

New study reveals that disrupting translation fidelity in tumor cells boosts their immunogenicity. TYW2 knockout triggers aberrant peptides, enhancing T cell response and sensitivity to PD-1 blockade - a novel path to cancer immunotherapy. #CancerResearch #Immunotherapy dlvr.it/TKlQfC

A Proffered Abstract at #AACR2025: New from the Human Tumor Atlas Network: Multi-modal profiling of HR+ metastatic breast cancer reveals tumor-intrinsic and microenvironmental programs driving CDK4/6 inhibitor resistance. Largest spatially resolved MBC cohort to date aacrjournals.org/cancerres/ar...